Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000950170-25-106741
Filing Date
2025-08-11
Accepted
2025-08-11 18:12:42
Documents
2
Period of Report
2025-08-07

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 17056
2 EX-24.DOCX bbio-ex24_docx.htm EX-24.DOCX 10848
  Complete submission text file 0000950170-25-106741.txt   29447
Mailing Address C/O BRIDGEBIO PHARMA, INC. 3160 PORTER DR, STE 250 PALO ALTO CA 94304
Business Address
Kumar Neil (Reporting) CIK: 0001742485 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-38959 | Film No.: 251203342

Mailing Address 3160 PORTER DR. SUITE 250 PALO ALTO CA 94304
Business Address 3160 PORTER DR. SUITE 250 PALO ALTO CA 94304 (650) 391-9740
BridgeBio Pharma, Inc. (Issuer) CIK: 0001743881 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)